CDC Issues Guidance on COVID-19 Rebound After Paxlovid Treatment


Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) continues to be really helpful for early stage therapy of delicate to average COVID-19 amongst people at high risk of progression to extreme illness, regardless of experiences of COVID-19 rebound, in keeping with a well being advisory issued by the Facilities for Illness Management and Prevention (CDC).

The antiviral agent, which was authorized for emergency use by the Meals and Drug Administration (FDA) in December 2021, consists of nirmatrelvir, a SARS-CoV-2 foremost protease inhibitor, and ritonavir, a HIV-1 protease inhibitor and CYP3A inhibitor.

Current case experiences counsel that some sufferers handled with Paxlovid might have a recurrence of COVID-19 signs 2 to eight days after finishing the 5-day course of therapy. In these circumstances, sufferers had examined destructive for COVID-19 following therapy after which subsequently examined optimistic. Each the sickness and the optimistic check outcomes resolved on common 3 days later with out the necessity for extra therapy.


Proceed Studying

In line with the CDC, “a quick return of signs could also be a part of the pure historical past of SARS-CoV-2 an infection in some individuals, impartial of therapy with Paxlovid and no matter vaccination standing.” Primarily based on info from case experiences, the recurrence of COVID-19 was not attributed to SARS-CoV-2 reinfection or the event of resistance to Paxlovid.

At present, there isn’t any proof to point that extra therapy for COVID-19 is required for sufferers who expertise COVID-19 rebound after Paxlovid therapy; monitoring continues to be essentially the most acceptable administration. Sufferers ought to be suggested to take precautions to prevent further transmission. In circumstances the place rebound signs persist or worsen, scientific analysis ought to be thought-about.

Well being care suppliers are additionally inspired to report cases of COVID-19 rebound to Pfizer and to the FDA’s MedWatch. The Paxlovid truth sheet for well being care suppliers may be discovered here.

Reference

COVID-19 rebound after Paxlovid therapy. CDC Well being Alert Community. Accessed Might 24, 2022. https://emergency.cdc.gov/han/2022/han00467.asp

This text initially appeared on MPR

Leave a Comment